CG
SLXP

Clinton Group’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Clinton Group’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-12,919
Closed -$855K – 461
2013
Q2 		$855K Buy
+12,919
New +$739K 0.28% 59

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Clinton Group's SLXP Position: Q3 2013 in Review

Clinton Group sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2013, closing a stake of 12,919 shares — an estimated $855K sold.

Clinton Group first reported a position in SLXP in Q2 2013 and held it in 1 quarter. The position peaked at $855K in Q2 2013. 251 funds tracked by Wall St. Rank hold SLXP as of Q3 2013.

  • Clinton Group reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2013 after selling out during the quarter.
  • Clinton Group sold 12,919 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2013, an estimated $855K.
  • Clinton Group first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 1 quarter.
  • Clinton Group's SALIX PHARMACEUTICALS LTD DEL position peaked at $855K in Q2 2013.
  • 251 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2013.

Based on Clinton Group's 13F filing for Q3 2013, filed 12 Nov 2013.